Wenlong Shao1, Hanzhang Chen1, Jianxing He1. 1. 1 Department of Cardiothoracic Surgery, 2 State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China ; 3 Key Cite of National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China.
Abstract
BACKGROUND: Lung cancer is the most commonly diagnosed cancer as well as the leading cause of cancer death worldwide. Observational studies on the prognostic role of SOX-2 in non-small-cell lung cancer (NSCLC) are controversial. METHODS: To clarify the impact of SOX-2 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios and their corresponding 95% confidence intervals (95% CI) were calculated in terms of overall survival. RESULTS: A total of seven studies with 1,944 patients were evaluable for this meta-analysis. The studies were categorized by histology, disease stage and patient race. Our results suggested that SOX-2 overexpression had a favorable impact on survival of patients with NSCLC, the HR (95% CI) was 0.57 (0.48 to 0.65). However, highly significant heterogeneity was detected among these studies (I(2)=76.7%, P=0.000). CONCLUSIONS: SOX-2 overexpression indicates a favorable prognosis for patients with NSCLC.
BACKGROUND:Lung cancer is the most commonly diagnosed cancer as well as the leading cause of cancer death worldwide. Observational studies on the prognostic role of SOX-2 in non-small-cell lung cancer (NSCLC) are controversial. METHODS: To clarify the impact of SOX-2 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios and their corresponding 95% confidence intervals (95% CI) were calculated in terms of overall survival. RESULTS: A total of seven studies with 1,944 patients were evaluable for this meta-analysis. The studies were categorized by histology, disease stage and patient race. Our results suggested that SOX-2 overexpression had a favorable impact on survival of patients with NSCLC, the HR (95% CI) was 0.57 (0.48 to 0.65). However, highly significant heterogeneity was detected among these studies (I(2)=76.7%, P=0.000). CONCLUSIONS:SOX-2 overexpression indicates a favorable prognosis for patients with NSCLC.
Authors: Cristina Gontan; Anne de Munck; Marcel Vermeij; Frank Grosveld; Dick Tibboel; Robbert Rottier Journal: Dev Biol Date: 2008-02-29 Impact factor: 3.582
Authors: B Martin; M Paesmans; T Berghmans; F Branle; L Ghisdal; C Mascaux; A-P Meert; E Steels; F Vallot; J-M Verdebout; J-J Lafitte; J-P Sculier Journal: Br J Cancer Date: 2003-07-07 Impact factor: 7.640
Authors: B Martin; M Paesmans; C Mascaux; T Berghmans; P Lothaire; A-P Meert; J-J Lafitte; J-P Sculier Journal: Br J Cancer Date: 2004-12-13 Impact factor: 7.640